ATAI Life Sciences BV (ATAI) - Cash Flow Conversion Efficiency
Based on the latest financial reports, ATAI Life Sciences BV (ATAI) has a cash flow conversion efficiency ratio of -0.106x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-21.09 Million) by net assets ($198.78 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See ATAI defensive interval ratio to measure how many days the company can operate on defensive assets alone.
ATAI Life Sciences BV - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how ATAI Life Sciences BV's cash flow conversion efficiency has evolved over time, based on yearly financial data.
ATAI Life Sciences BV Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ATAI Life Sciences BV ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Guangdong Yizumi Precision Machinery Co Ltd
SHE:300415
|
-0.008x |
|
Ufuk Yatirim Yonetim Ve Gayrimenkul AS
IS:UFUK
|
-0.002x |
|
Tangshan Jidong Cement Co Ltd
SHE:000401
|
0.047x |
|
Bilia AB (publ)
ST:BILI-A
|
0.122x |
|
Paradox Interactive AB (publ)
ST:PDX
|
0.119x |
|
Hotel Shilla
KO:008770
|
-0.137x |
|
Youngone Holdi
KO:009970
|
0.067x |
|
Telecom Argentina SA ADR
NYSE:TEO
|
0.093x |
Annual Cash Flow Conversion Efficiency for ATAI Life Sciences BV (2019–2025)
The table below shows the annual cash flow conversion efficiency of ATAI Life Sciences BV from 2019 to 2025. For the full company profile with market capitalisation and key ratios, see ATAI Life Sciences BV stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $222.00 Million | $-102.67 Million | -0.462x | +34.61% |
| 2024-12-31 | $116.55 Million | $-82.44 Million | -0.707x | -105.43% |
| 2023-12-31 | $244.32 Million | $-84.12 Million | -0.344x | +12.41% |
| 2022-12-31 | $265.77 Million | $-104.47 Million | -0.393x | -139.88% |
| 2021-12-31 | $385.96 Million | $-63.25 Million | -0.164x | +24.74% |
| 2020-12-31 | $95.37 Million | $-20.77 Million | -0.218x | -65.90% |
| 2019-12-31 | $59.78 Million | $-7.85 Million | -0.131x | -- |
About ATAI Life Sciences BV
AtaiBeckley Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada. The company develops BPL-003, an intranasal formulation of the benzoate salt form of mebufotenin that is in Phase 2a and 2b clinical studies for treatment resistant depression (TRD) and alcohol use disorder… Read more